Home » Stronger Exelon Patch Wins FDA Nod
Stronger Exelon Patch Wins FDA Nod
A transdermal patch delivering rivastigmine (Exelon) at a 40 percent higher rate than the previous maximum strength has been cleared by the FDA for patients with mild to moderate Alzheimer's disease, its manufacturer said.
MedPage Today
MedPage Today
Upcoming Events
-
07May
-
14May
-
30May